Gå till innehåll

Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Necitumumab

Summary

Risk. Exempt.

 

This information is taken from an assessment report.

Detailed information

Assessment report

Assessment report for Portrazza (necitumumab), 17 December 2015, EMA/CHMP/15391/2016.

"Necitumumab is a protein, which is expected to biodegrade in the environment and not be a significant risk to the environment. Thus, according to the “Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use” (EMEA/CHMP/SWP/4447/00), necitumumab is exempt from preparation of an Environmental Risk Assessment as the product and excipients do not pose a significant risk to the environment."

Fass environmental information

Environmental information is missing on fass.se (2019-09-04). It is voluntary for manufacturers to provide information about environmental impact on fass.se.

Author: Health and Medical Care Administration, Region Stockholm